title: Growth hormone response to thyrotrophin releasing hormone in women with polycystic ovarian syndrome.
abstract: Recent clinical studies have suggested that women with polycystic ovarian syndrome (PCOS) may have disturbances of growth hormone (GH) kinetics and the GH/insulin-like growth factor (IGF)-I system. The knowledge that in various metabolic abnormalities there is a paradoxical sensitivity of pituitary somatotrophs to thyrotrophin releasing hormone (TRH) administration led to this investigation of the GH secretory response to TRH in women with PCOS. Twenty-four women with PCOS and 18 control women were studied. TRH was given as a single i.v. injection (time 0) and blood samples for GH measurements were obtained at -15, 0, 15, 30, 60 and 90 min. The GH responses were expressed as the area under the curve (AUC) or the differences from the basal value (Deltamax). The GH response to TRH (mean +/- SEM) was greater in women with PCOS (Deltamax 2.47 +/- 1. 73 versus 0.47 +/- 0.06 ng/ml, P < 0.05 and GH AUC 8.05 +/- 2.10 versus 2.58 +/- 0.18 ng/ml/90 min, P < 0.05). According to GH response to TRH, two PCOS subgroups were identified: (i) normal responders (n = 14) who showed Deltamax GH response (0.36 +/- 0.06 ng/ml)and GH AUC (1.93 +/- 0.64 ng/ml/90 min) similar to that in the controls and (ii) over-responders (n +/- 10) who showed a paradoxical increase in GH concentrations in response to TRH (Deltamax GH response 5.43 +/- 1.27 ng/ml and GH AUC 16.62 +/- 3.51 ng/ml per 90 min) that was significantly higher than in normally responding PCOS patients (P < 0.0001) or in controls (P < 0.0001). These data demonstrate an enhanced GH response to TRH administration in a subgroup of women with PCOS.
authors.affiliation: Department of Endocrinology, PANAGIA Hospital, Thessaloniki, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Kaltsas
authors.forename: N
authors.initials: N
authors.lastname: Pontikides
authors.forename: G E
authors.initials: GE
authors.lastname: Krassas
authors.forename: K
authors.initials: K
authors.lastname: Seferiadis
authors.forename: D
authors.initials: D
authors.lastname: Lolis
authors.forename: I E
authors.initials: IE
authors.lastname: Messinis
mesh_terms: D000328:Adult; D000735:Androstenedione / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D004958:Estradiol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007700:Kinetics; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D013739:Testosterone / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage
chemical_list: D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D019382:Human Growth Hormone; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D007334:Insulin-Like Growth Factor I